On Monday, Ovid Therapeutics Inc (NASDAQ: OVID) opened lower -5.68% from the last session, before settling in for the closing price of $1.76. Price fluctuations for OVID have ranged from $0.24 to $2.01 over the past 52 weeks.
During the last 5-year period, the sales growth of Healthcare Sector giant was 24.72%. Company’s average yearly earnings per share was noted -27.87% at the time writing. With a float of $58.32 million, this company’s outstanding shares have now reached $71.15 million.
Ovid Therapeutics Inc (OVID) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ovid Therapeutics Inc is 18.10%, while institutional ownership is 71.72%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.
Ovid Therapeutics Inc (OVID) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.13 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.17) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.87% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.20% during the next five years compared to 24.72% growth over the previous five years of trading.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Check out the current performance indicators for Ovid Therapeutics Inc (OVID). In the past quarter, the stock posted a quick ratio of 4.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.51, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.43 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Looking closely at Ovid Therapeutics Inc (NASDAQ: OVID), its last 5-days average volume was 1.31 million, which is a drop from its year-to-date volume of 1.78 million. As of the previous 9 days, the stock’s Stochastic %D was 57.44%.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 76.03%, which indicates a significant increase from 64.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1293 in the past 14 days, which was lower than the 0.1366 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5161, while its 200-day Moving Average is $0.8966. However, in the short run, Ovid Therapeutics Inc’s stock first resistance to watch stands at $1.7383. Second resistance stands at $1.8167. The third major resistance level sits at $1.8633. If the price goes on to break the first support level at $1.6133, it is likely to go to the next support level at $1.5667. Now, if the price goes above the second support level, the third support stands at $1.4883.
Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats
There are currently 71,212K shares outstanding in the company with a market cap of 118.21 million. Presently, the company’s annual sales total 570 K according to its annual income of -26,430 K. Last quarter, the company’s sales amounted to 130 K and its income totaled -12,160 K.
